# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001370053-24-000011
Filing Date
2024-03-11
Accepted
2024-03-11 16:36:00
Documents
140
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | anab-20231231.htm iXBRL | 10-K | 1804757
2 | EX-10.18 | centessalicenseagreement.htm | EX-10.18 | 160332
3 | EX-10.19 | tesaroamd5tolicenseagree.htm | EX-10.19 | 11513
4 | EX-21.1 | anab-12312023xexx211.htm | EX-21.1 | 2452
5 | EX-23.1 | anab-12312023xexx231.htm | EX-23.1 | 2036
6 | EX-31.1 | anab-12312023x10kxexx311.htm | EX-31.1 | 8567
7 | EX-31.2 | anab-12312023x10kxexx312.htm | EX-31.2 | 8308
8 | EX-32.1 | anab-12312023x10kxexx321.htm | EX-32.1 | 5093
9 | EX-32.2 | anab-12312023x10kxexx322.htm | EX-32.2 | 4815
10 | EX-97 | clawbackpolicyapproved9-.htm | EX-97 | 25415
16 |  | anab-20231231_g1.jpg | GRAPHIC | 161904
17 |  | centessalicenseagreement001.jpg | GRAPHIC | 245134
18 |  | centessalicenseagreement002.jpg | GRAPHIC | 247056
19 |  | centessalicenseagreement003.jpg | GRAPHIC | 284052
20 |  | centessalicenseagreement004.jpg | GRAPHIC | 247529
21 |  | centessalicenseagreement005.jpg | GRAPHIC | 278057
22 |  | centessalicenseagreement006.jpg | GRAPHIC | 226936
23 |  | centessalicenseagreement007.jpg | GRAPHIC | 255357
24 |  | centessalicenseagreement008.jpg | GRAPHIC | 280677
25 |  | centessalicenseagreement009.jpg | GRAPHIC | 270329
26 |  | centessalicenseagreement010.jpg | GRAPHIC | 229849
27 |  | centessalicenseagreement011.jpg | GRAPHIC | 255454
28 |  | centessalicenseagreement012.jpg | GRAPHIC | 273386
29 |  | centessalicenseagreement013.jpg | GRAPHIC | 196832
30 |  | centessalicenseagreement014.jpg | GRAPHIC | 214062
31 |  | centessalicenseagreement015.jpg | GRAPHIC | 224458
32 |  | centessalicenseagreement016.jpg | GRAPHIC | 274250
33 |  | centessalicenseagreement017.jpg | GRAPHIC | 242588
34 |  | centessalicenseagreement018.jpg | GRAPHIC | 242839
35 |  | centessalicenseagreement019.jpg | GRAPHIC | 215108
36 |  | centessalicenseagreement020.jpg | GRAPHIC | 294691
37 |  | centessalicenseagreement021.jpg | GRAPHIC | 307381
38 |  | centessalicenseagreement022.jpg | GRAPHIC | 320900
39 |  | centessalicenseagreement023.jpg | GRAPHIC | 267259
40 |  | centessalicenseagreement024.jpg | GRAPHIC | 249812
41 |  | centessalicenseagreement025.jpg | GRAPHIC | 243527
42 |  | centessalicenseagreement026.jpg | GRAPHIC | 266006
43 |  | centessalicenseagreement027.jpg | GRAPHIC | 286229
44 |  | centessalicenseagreement028.jpg | GRAPHIC | 327024
45 |  | centessalicenseagreement029.jpg | GRAPHIC | 324489
46 |  | centessalicenseagreement030.jpg | GRAPHIC | 319062
47 |  | centessalicenseagreement031.jpg | GRAPHIC | 293881
48 |  | centessalicenseagreement032.jpg | GRAPHIC | 316331
49 |  | centessalicenseagreement033.jpg | GRAPHIC | 310641
50 |  | centessalicenseagreement034.jpg | GRAPHIC | 290362
51 |  | centessalicenseagreement035.jpg | GRAPHIC | 276554
52 |  | centessalicenseagreement036.jpg | GRAPHIC | 309921
53 |  | centessalicenseagreement037.jpg | GRAPHIC | 267269
54 |  | centessalicenseagreement038.jpg | GRAPHIC | 317894
55 |  | centessalicenseagreement039.jpg | GRAPHIC | 283579
56 |  | centessalicenseagreement040.jpg | GRAPHIC | 273108
57 |  | centessalicenseagreement041.jpg | GRAPHIC | 302841
58 |  | centessalicenseagreement042.jpg | GRAPHIC | 144830
59 |  | centessalicenseagreement043.jpg | GRAPHIC | 47275
60 |  | clawbackpolicyapproved9-001.jpg | GRAPHIC | 197488
61 |  | clawbackpolicyapproved9-002.jpg | GRAPHIC | 207074
62 |  | clawbackpolicyapproved9-003.jpg | GRAPHIC | 255271
63 |  | clawbackpolicyapproved9-004.jpg | GRAPHIC | 244269
64 |  | clawbackpolicyapproved9-005.jpg | GRAPHIC | 232115
65 |  | clawbackpolicyapproved9-006.jpg | GRAPHIC | 269488
66 |  | clawbackpolicyapproved9-007.jpg | GRAPHIC | 76702
67 |  | clawbackpolicyapproved9-008.jpg | GRAPHIC | 164262
68 |  | clawbackpolicyapproved9-009.jpg | GRAPHIC | 166153
69 |  | tesaroamd5tolicenseagree001.jpg | GRAPHIC | 245402
70 |  | tesaroamd5tolicenseagree002.jpg | GRAPHIC | 158762
71 |  | tesaroamd5tolicenseagree003.jpg | GRAPHIC | 60293
72 |  | tesaroamd5tolicenseagree004.jpg | GRAPHIC | 25021
73 |  | tesaroamd5tolicenseagree005.jpg | GRAPHIC | 25078
| Complete submission text file | 0001370053-24-000011.txt |  | 27894083

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | anab-20231231.xsd | EX-101.SCH | 58871
12 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | anab-20231231_cal.xml | EX-101.CAL | 74291
13 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | anab-20231231_def.xml | EX-101.DEF | 225590
14 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | anab-20231231_lab.xml | EX-101.LAB | 722342
15 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | anab-20231231_pre.xml | EX-101.PRE | 475403
142 | EXTRACTED XBRL INSTANCE DOCUMENT | anab-20231231_htm.xml | XML | 1175944

Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

EIN.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37985 | Film No.: 24738601
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)